Prime Medicine, Inc. Common Stock

PRMENASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
2.99 USD
↘ 0.07 (2.13%)AT CLOSE (03:59 PM EDT)
3.01
↗ 0.02 (0.67%)
POST MARKET (AS OF 05:34 PM EDT)
Post Market
AS OF 05:34 PM EDT
3.01
↗ 0.02 (0.67%)
🟢Market: OPEN

Prime Medicine, Inc. Common Stock (PRME) trades at $3.01 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Oct 1, 2026.

Open?$3.05
High?$3.11
Low?$2.98
Prev. Close?$3.06
Volume?2.8M
Avg. Volume?3.2M
VWAP?$3.03
Rel. Volume?0.87x
Bid / Ask
Bid?$2.59 × 100
Ask?$3.48 × 100
Spread?$0.89
Midpoint?$3.04
Valuation & Ratios
Market Cap?555.0M
Shares Out?181.4M
Float?95.7M
Float %?52.7%
P/E Ratio?N/A
P/B Ratio?13.94
EPS?-$1.04
Dividend?0.00%
Ex-Dividend?N/A
RelatedBEAMCRSP
News
Profile
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
146
Market Cap
554.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.primemedicine.com
Listed
2022-10-20
Address
60 FIRST ST.
CAMBRIDGE, MA 02141
Phone: 617-465-0013
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
75
Short Sent.?
15
Piotroski F-Score?1/9Weak
Altman Z-Score?-6.28Distress
Confidence?53%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?33.59%Squeeze Risk
Short Interest?32.1M
Days to Cover?12.3
Free Float95.7M
Avg Daily Volume2.6M
Settlement Date2026-09-15
Financial Health
Current Ratio?1.95Adequate
Quick Ratio?1.95Adequate
Cash Ratio?0.95Adequate
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 2 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
33
S&P
13
13.94HIGH▾
P/S?
Peers
67
S&P
3
136.27HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.7CHEAP▾
EV/Sales?
Peers
67
S&P
3
124.62HIGH▾
Returns & Efficiency
ROE?
S&P
3
-472.0%WEAK▾
ROA?
S&P
3
-75.4%WEAK▾
Cash Flow & Enterprise
FCF?$-156848000
Enterprise Value?$507.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist